MIR216B

Summary

MIR216B (microRNA 216b, HGNC:33668) is a microRNA gene on chromosome 2p16.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100126319 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:33668
Approved symbol	MIR216B
Name	microRNA 216b
Location	2p16.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-216b
Ensembl gene	ENSG00000211520
Ensembl biotype	miRNA
Entrez	100126319
RNAcentral	URS000075EC67 — miRNA, 82 nt, 5 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000390186

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000390186 — 1 exons

Exon	Start	End
ENSE00001507613	56000714	56000795

Expression profiles

Bgee: expression breadth broad, 18 present calls, max score 74.91.

Top tissues by expression

18 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	74.91	gold quality
body of pancreas	UBERON:0001150	70.40	gold quality
omental fat pad	UBERON:0010414	68.47	gold quality
body of stomach	UBERON:0001161	68.07	gold quality
lower esophagus muscularis layer	UBERON:0035833	66.20	gold quality
intestine	UBERON:0000160	64.76	gold quality
minor salivary gland	UBERON:0001830	63.52	gold quality
stomach	UBERON:0000945	63.27	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	62.77	gold quality
substantia nigra	UBERON:0002038	61.45	gold quality
skin of leg	UBERON:0001511	61.38	gold quality
muscle layer of sigmoid colon	UBERON:0035805	59.46	gold quality
lung	UBERON:0002048	59.27	gold quality
skin of abdomen	UBERON:0001416	58.52	gold quality
nucleus accumbens	UBERON:0001882	56.94	gold quality
prostate gland	UBERON:0002367	54.30	gold quality
corpus callosum	UBERON:0002336	41.79	silver quality
left testis	UBERON:0004533	39.57	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.16

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 36)

• Altogether, we concluded that miR-216b regulated both autophagy and apoptosis by modulating Beclin 1 in human Tenon’s fibroblasts treated with hydroxycamptothecin. (PMID:24681041)
• MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway (PMID:25741595)
• Study demonstrated that plasma miRNA-216a/b might serve as potential biomarkers for the diagnosis of esophageal squamous cell carcinoma (ESCC) and dysregulation of miRNA-216a/b might be involved in the progression of ESCC. (PMID:26989293)
• MiR-216b directly targets c-Jun, thereby reducing AP-1-dependent transcription and sensitizing cells to ER stress-dependent apoptosis. (PMID:27173017)
• miRNAs regulate UGT 2B7, 2B4, and 2B10 expression (PMID:27474751)
• there is a HIF-2alpha-MALAT1-miR-216b axis regulating multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy. (PMID:27524242)
• In summary, the study identifies miR-216b as a regulator of SDCBP expression in breast cancer which can potentially be targeted for developing newer therapies for the effective treatment of this killer disease. (PMID:27720715)
• Results demonstrated that miR-216b is a tumor suppressor in melanoma, identified the FOXM1 signaling pathway as a target of miR-216b action. (PMID:28225180)
• Data show that the mRNA level of poly(ADP-ribose) polymerase (PARP)-1 was significantly regulated by miR-216b. (PMID:28281524)
• miR-216b expression was a valuable biomarker correlated with disease recurrence in acute myeloid leukemia. (PMID:28884855)
• FOXM1 expression could be suppressed by miR-216b via direct binding to FOXM1 3’-UTR and miR-216b could inhibit cell proliferation by regulating FOXM1 related Wnt/beta-catenin signal pathway. MiR-216b level is related to prognosis in cervical cancer patients and may serve as a potential prognostic marker. (PMID:28978307)
• miR-216b enhances the efficacy of vemurafenib and reverses drug resistance by targeting Beclin-1, UVRAG and ATG5 in melanoma. (PMID:28982601)
• These results suggested that miR216b acted as a tumor suppressor in glioma by directly targeting MTDH and that the miR216b/MTDH axis may be an effective therapeutic target for the treatment of patients with this disease (PMID:29152659)
• SNHG7 positively regulated GALNT1 level through sponging miR-216b, and played an oncogenic role in colorectal cancer progression. (PMID:29915311)
• MiR-216b exerted its tumor suppressor function through inhibiting the KRAS-related MAPK/ERK and PI3K/AKT pathways. (PMID:30231239)
• These findings may provide novel insights into the molecular mechanism of miR-216b and FoxM1 in the progression of Osteosarcoma (OS) , and suggested that miR-216b may serve as a potential tumor inhibitor of OS by targeting FoxM1. (PMID:30302807)
• We observed that the designed ss-miR-216b mimics engaged AGO2 to promote the silencing of KRAS. We also tested a new delivery strategy based on the use of palmityl-oleyl-phosphatidylcholine (POPC) liposomes functionalized with ss-miR-216b conjugated with two palmityl chains and a lipid-modified cell penetrating peptide . These versatile nanoparticles suppressed oncogenic KRAS in pancreatic ductal adenocarcinoma cells (PMID:30306823)
• Long non-coding RNA 00152 promotes cell proliferation in cervical cancer via regulating miR-216b-5p/HOXA1 axis. (PMID:31114990)
• Low miR216b expression is associated with breast cancer. (PMID:31605710)
• Collectively, serum exosomal miR-216b might be used as a potential diagnostic and prognostic biomarker for non-small cell lung cancer (NSCLC). (PMID:31771047)
• MicroRNA-216b suppresses the cell growth of hepatocellular carcinoma by inhibiting Ubiquitin-specific peptidase 28 expression. (PMID:32053284)
• MicroRNA-216b regulates cell proliferation, invasion and cycle progression via interaction with cyclin T2 in gastric cancer. (PMID:32058347)
• Therapeutic targeting of miRNA-216b in cancer. (PMID:32387443)
• LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. (PMID:32432750)
• Correlation between carotid atherosclerotic plaque properties and serum levels of lncRNA CCAT2 and miRNA-216b. (PMID:32633397)
• Dysregulation of lnc-SNHG1 and miR-216b-5p correlate with chemoresistance and indicate poor prognosis of serous epithelial ovarian cancer. (PMID:33302997)
• LncRNA KCNQ1OT1 acts as miR-216b-5p sponge to promote colorectal cancer progression via up-regulating ZNF146. (PMID:33394291)
• MiR-216b regulates the tumorigenesis of gastric cancer by targeting PXN. (PMID:33422779)
• MiR-216b inhibits gastric cancer proliferation and migration by targeting PARK7. (PMID:33433409)
• LncRNA MYCNOS promotes glioblastoma cell proliferation by regulating miR-216b/FOXM1 axis. (PMID:33871770)
• Long Noncoding RNA LINC01518 Modulates Proliferation and Migration in TGF-beta1-Treated Human Tenon Capsule Fibroblast Cells Through the Regulation of hsa-miR-216b-5p. (PMID:33993456)
• MicroRNA-216b targets HK2 to potentiate autophagy and apoptosis of breast cancer cells via the mTOR signaling pathway. (PMID:34345220)
• The expression of miRNA-216b is negatively correlated with 18F-FDG uptake in non-small cell lung cancer. (PMID:34470640)
• Ultrasound microbubbles-mediated miR-216b affects MALAT1-miRNA axis in non-small cell lung cancer cells. (PMID:34896788)
• LncRNA-SNHG1 promotes paclitaxel resistance of gastric cancer cells through modulating the miR-216b-5p-hexokianse 2 axis. (PMID:36548909)
• [LncRNA RPL22P1-201 affects prostate cancer cell proliferation, cell cycle, and sensitivity to docetaxel by regulating miR-216b-5p expression]. (PMID:38639656)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	dre-mir-216a	ENSDARG00000081608
danio_rerio	dre-mir-216b	ENSDARG00000083359
mus_musculus	Mir216b	ENSMUSG00000076318
rattus_norvegicus	Mir216b	ENSRNOG00000036371

Paralogs (1): MIR216A (ENSG00000207798)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.